Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives

被引:0
作者
E. Krasniqi
G. Barchiesi
L. Pizzuti
M. Mazzotta
A. Venuti
M. Maugeri-Saccà
G. Sanguineti
G. Massimiani
D. Sergi
S. Carpano
P. Marchetti
S. Tomao
T. Gamucci
R. De Maria
F. Tomao
C. Natoli
N. Tinari
G. Ciliberto
M. Barba
P. Vici
机构
[1] IRCCS Regina Elena National Cancer Institute,Division of Medical Oncology 2
[2] “Sapienza” University of Rome,Department of Clinical and Molecular Medicine
[3] IRCSS Regina Elena National Cancer Institute,HPV
[4] IRCCS Regina Elena National Cancer Institute,UNIT, UOSD Tumor Immunology and Immunotherapy, Department of Research, Advanced Diagnostic and Technological Innovation (RIDAIT), Translational Research Functional Departmental Area
[5] Policlinico Umberto I,Department of Radiation Oncology
[6] ‘Sapienza’ University of Rome,Medical Oncology Unit B
[7] Sandro Pertini Hospital,Department of Radiological, Oncological and Anatomo
[8] Catholic University of the Sacred Heart,Pathological Sciences, Policlinico Umberto I
[9] Policlinico Universitario “A. Gemelli”,Medical Oncology
[10] “Sapienza” University of Rome,Institute of General Pathology
[11] G. d’Annunzio University,Department of Medical Oncology
[12] IRCCS Regina Elena National Cancer Institute,Department of Gynecology
来源
Journal of Hematology & Oncology | / 12卷
关键词
Metastatic; Early; Breast cancer; Immunotherapy; Vaccine; HER2+;
D O I
暂无
中图分类号
学科分类号
摘要
Breast cancer (BC) is a complex disease with primary or acquired incurability characteristics in a significant part of patients. Immunotherapeutical agents represent an emerging option for breast cancer treatment, including the human epidermal growth factor 2 positive (HER2+) subtype. The immune system holds the ability to spontaneously implement a defensive response against HER2+ BC cells through complex mechanisms which can be exploited to modulate this response for obtaining a clinical benefit. Initial immune system modulating strategies consisted mostly in vaccine therapies, which are still being investigated and improved. However, the entrance of trastuzumab into the scenery of HER2+ BC treatment was the real game changing event, which embodied a dominant immune-mediated mechanism. More recently, the advent of the immune checkpoint inhibitors has caused a new paradigm shift for immuno-oncology, with promising initial results also for HER2+ BC. Breast cancer has been traditionally considered poorly immunogenic, being characterized by relatively low tumor mutation burden (TMB). Nevertheless, recent evidence has revealed high tumor infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in a considerable proportion of HER2+ BC patients. This may translate into a higher potential to elicit anti-cancer response and, therefore, wider possibilities for the use and implementation of immunotherapy in this subset of BC patients. We are herein presenting and critically discussing the most representative evidence concerning immunotherapy in HER2+ BC cancer, both singularly and in combination with therapeutic agents acting throughout HER2-block, immune checkpoint inhibition and anti-cancer vaccines. The reader will be also provided with hints concerning potential future projection of the most promising immutherapeutic agents and approaches for the disease of interest.
引用
收藏
相关论文
共 947 条
[1]  
Barnard ME(2015)Established breast cancer risk factors and risk of intrinsic tumor subtypes Biochim Biophys Acta 1856 73-85
[2]  
Boeke CE(2009)Supervised risk predictor of breast cancer based on intrinsic subtypes J Clin Oncol 27 1160-1167
[3]  
Tamimi RM(2015)Immunohistochemical, genetic and epigenetic profiles of hereditary and triple negative breast cancers. Relevance in personalized medicine Am J Cancer Res 5 2330-2343
[4]  
Parker JS(2012)Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis Breast Cancer Res Treat 134 957-967
[5]  
Mullins M(2013)Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study Lancet Oncol 14 461-471
[6]  
Cheang MC(2006)Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2733-2743
[7]  
Leung S(2017)Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial Lancet Oncol 18 732-742
[8]  
Voduc D(2013)Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance Clin Breast Cancer 13 223-232
[9]  
Vickery T(2013)Signatures of mutational processes in human cancer Nature 500 415-421
[10]  
Murria R(2013)Cancer genome landscapes Science 339 1546-1558